^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PTK2B (Protein Tyrosine Kinase 2 Beta)

    i
    Other names: PTK2B, Protein Tyrosine Kinase 2 Beta, RAFTK, CADTK, CAKB, PYK2, FAK2, PTK, Calcium-Regulated Non-Receptor Proline-Rich Tyrosine Kinase, Related Adhesion Focal Tyrosine Kinase, Calcium-Dependent Tyrosine Kinase, Protein-Tyrosine Kinase 2-Beta, Proline-Rich Tyrosine Kinase 2, Cell Adhesion Kinase Beta, Focal Adhesion Kinase 2, CAK-Beta, FADK 2, PTK2B Protein Tyrosine Kinase 2 Beta, Protein Kinase B, FADK2, PKB
    Associations

    News

    Trials
    2ms
    Microwave dynamic therapy induces ferroptosis in colorectal cancer by targeting PTK2B to regulate STAT3-mediated GPX4 expression. (PubMed, Mol Biomed)
    MWDT inhibited PTK2B expression, suppressed STAT3 phosphorylation, and subsequently downregulated GPX4 transcription, thereby inducing ferroptosis. Our findings are the first to demonstrate that MWDT mediates ferroptosis in CRC via the PTK2B/STAT3/GPX4 axis, offering novel theoretical insights for its comprehensive treatment.
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • GPX4 (Glutathione Peroxidase 4) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    4ms
    Discovery and Evaluation of Novel Sulfonamide Derivatives Targeting Aromatase in ER+ Breast Cancer. (PubMed, Pharmaceuticals (Basel))
    Their binding affinity and specificity support further development. EGFR and PTK2B may enable a broader, multi-target approach.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    |
    ER positive
    12ms
    Prognostic feature based on androgen-responsive genes in bladder cancer and screening for potential targeted drugs. (PubMed, BioData Min)
    ARGs played an important role in the progression, immune infiltration, and prognosis of BLCA. The ARGs model has high accuracy in predicting the prognosis of BLCA patients and provides more effective medication guidelines.
    Journal
    |
    CDK6 (Cyclin-dependent kinase 6) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    |
    carmustine • fludarabine IV • AZD8186
    over1year
    Targeting PYK2 with heterobifunctional T6BP helps mitigate MASLD and MASH-HCC progression. (PubMed, J Hepatol)
    Our study revealed a previously unknown mechanism: identification of T6BP as a key eliminator of fatty liver strongly contributes to the development of promising therapeutic targets, and the discovery of crucial fragments of T6BP-based pharmacon that interrupt PYK2 dimerization are novel and viable treatments for fatty liver and its advanced symptoms and complications.
    Journal
    |
    TYK2 (Tyrosine Kinase 2) • PTK2B (Protein Tyrosine Kinase 2 Beta) • TRAF6 (TNF Receptor Associated Factor 6)
    over1year
    Multi-omics data analysis reveals the complex roles of age in differentiated thyroid cancer. (PubMed, Heliyon)
    Finally, we constructed a prognosis prediction model based on three age-related genes (PTK2B, E2F1, and GHR) that showed satisfactory performance in predicting patients prognosis. We comprehensively investigated the complex interplay between age and biological features of DTC, which may provide new insights into the role of aging in DTC.
    Journal
    |
    CD8 (cluster of differentiation 8) • E2F1 (E2F transcription factor 1) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    over1year
    Prediction of immunotherapy response of bladder cancer with a pyroptosis-related signature indicating tumor immune microenvironment. (PubMed, Front Pharmacol)
    PRGs are closely associated with TME and oncogenic pathways. PRGs score is a promising indicator for predicting clinical outcome and immunotherapy response.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CDK6 (Cyclin-dependent kinase 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • SPINK1 (Serine peptidase inhibitor, kazal type 1) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    over1year
    Ethnicity-Based Variations in Focal Adhesion Kinase Signaling in Glioblastoma Gene Expression: A Study of the Puerto Rican Hispanic Population. (PubMed, Int J Mol Sci)
    The data acquired from cBioPortal for non-Puerto Rican Hispanic patients supported the correlations found in the Puerto Rican population for both sexes. Our findings reveal distinct correlations in gene expression patterns, particularly involving PTK2, PTK2B, NGFR, PDGFRB, and EGFR among Puerto Rican Hispanic patients when compared to non-Hispanic counterparts.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • NGFR (Nerve Growth Factor Receptor) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • PTK2 (Protein Tyrosine Kinase 2) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    almost2years
    Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. (PubMed, Gynecol Oncol)
    Avutometinib, and to a larger extent its combination with FAK inhibitor VS-4718, demonstrated promising in vivo activity against a KRAS wild-type LGSOC-PDX. These data support the ongoing registration-directed study (RAMP201/NCT04625270).
    Preclinical • Journal • Combination therapy
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ADRB2 (Adrenoceptor Beta 2) • PRKDC (Protein Kinase, DNA-Activated, Catalytic Subunit) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    |
    KRAS mutation • BRAF mutation • KRAS wild-type • RAS wild-type
    |
    Avmapki (avutometinib) • Fakzynja (defactinib) • VS-4718
    almost2years
    Lnc RNA LOC102163816 promotes proliferation of porcine follicular granulosa cells via miR-455-3p/PTK2B/PI3 K/AKT pathway. (PubMed, Endocrinology)
    Our results showed that LOC102163816 sponged miR-455-3p, promoting expression of protein tyrosine kinase 2 beta (PTK2B), thereby activating the PI3 K/AKT signaling pathway to regulate proliferation of porcine follicular GCs. These findings provide useful insights into follicular development.
    Preclinical • Journal
    |
    MALAT1 (Metastasis associated lung adenocarcinoma transcript 1) • TYK2 (Tyrosine Kinase 2) • MIR455 (MicroRNA 455) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    2years
    Enrichment Analysis and pharmacolologic target prediction of anti-proliferative thiazolopyrine AV25R on acute lympoblastic leukemia cell line RS4;11 (DGHO 2023)
    Our result provides first mechanistic understanding of the AV25R mode of action as an antiproliferative agent.
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • JAK2 (Janus kinase 2) • CHEK2 (Checkpoint kinase 2) • MAPK1 (Mitogen-activated protein kinase 1) • TGFB1 (Transforming Growth Factor Beta 1) • TYK2 (Tyrosine Kinase 2) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • PTK2B (Protein Tyrosine Kinase 2 Beta) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    over2years
    Identification of cuproptosis and immune-related gene prognostic signature in lung adenocarcinoma. (PubMed, Front Immunol)
    The results of the study indicate significantly reduced survival rates in both the training and validation sets among the high-risk group. Additionally, the high-risk group displayed lower levels of immune cell infiltration and expression of immune checkpoint compared to the low-risk group.
    Journal
    |
    CD79B (CD79b Molecule) • XBP1 (X-box-binding protein 1) • PTK2B (Protein Tyrosine Kinase 2 Beta)